In KEYNOTE-024 and KEYNOTE-042, pembrolizumab showed superior OS versus platinum-based chemotherapy in patients with advanced NSCLC with ≥50% and ≥1% PD-L1 expression on tumor cells, respectively,2 3 which provided the basis for the approval of pembrolizumab in this setting. This evidence concerns the gene CD274 and neoplasm.